- Lamivudine plus adefovir combination therapy for lamivudine resistance in hepatitis-B-related hepatocellular carcinoma patients
-
Kim JH, Ko SY, Choe WH, Kwon SY, Lee CH
- KMID: 1705205
- Clin Mol Hepatol.
- 2013 Sep;19(3):273-279.
- doi: 10.3350/cmh.2013.19.3.273
BACKGROUND/AIMS: Lamivudine (LAM) plus adefovir (ADV) combination therapy has been accepted as one of the best treatments for LAM-resistant chronic hepatitis B (CHB). The aim of this study was to... -
- CITED
-
- Close
- SHARE
-
- Close
